On Building A Better R&D Machine, Part 1: Pfizer’s R&D Chief Mikael Dolsten Talks Organizational Structure And Innovation
This article was originally published in The Pink Sheet Daily
Executive Summary
Since ascending to the top R&D spot at the world’s largest pharmaceutical company, Mikael Dolsten has taken the lead in focusing R&D at Pfizer and optimizing its portfolio. In Part 1 of a two-part interview with "The Pink Sheet" DAILY, Dolsten shares his thoughts on fine-tuning the R&D organization for speed and efficiency and on whether innovation can be repeated.
You may also be interested in...
Pharma At Barclays, In Brief
Executives presenting at the Barclays Capital Healthcare Conference on March 13-14 discussed everything from early pipeline progress to launch performance.
Xalkori And The Art Of Modern Drug Development
Pfizer developed crizotinib and its companion diagnostic in just four years after identifying an aberrant ALK gene as the target, spanning a corporate restructuring, the Wyeth integration, and the departure of senior staff in the R&D organization and oncology BU. The next year or so will tell whether Xalkori was a flash in the pan, or whether it marks the long awaited turnaround for Pfizer’s oncology business and a model for nimble drug development.
Pfizer Rare Disease Plans Back On Track With Resubmission of Tafamidis
Pfizer gained the therapy to treat a rare genetic neurologic disorder in its 2010 acquisition of folded protein company FoldRx.